AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

Axsome Therapeutics GAAP EPS of -$0.90 beats by $0.08 https://seekingalpha.com/news/3807524-axsome-therapeutics-gaap-eps-of--090-beats-by-008 Axsome Therapeutics press release (NASDAQ:AXSM): Q4 GAAP EPS of -$0.90 beats by $0.08. At December 31, 2021, Axsome had $86.5M of cash compared to $183.9 million at December 31, 2020. Axsome believes that its current cash, along with the remaining committed capital from the $300M term loan facility, is sufficient to fund anticipated operations, based on the current operating plan, which includes costs for the potential commercial launch of AXS-05 in MDD and AXS-07 in migraine, into 2024. Axsome expects that its operating expenses will increase year over year as it continues to build out the commercial function and further advance its pipeline.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update https://www.globenewswire.com/news-release/2022/03/01/2394104/33090/en/Axsome-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Business-Update.html

Gefühlt nur noch bis zum 01.03 😁 zumindest in meiner Welt

Bergab aber es Läuft. Wie lange dauert überhaupt diese AXS-05 Zulassung ,Gefühlte 3 Jahre???

Läuft

Ist ruhiger geworden....Adler.... ....in der Ruhe liegt die Kraft!

✌️

Weiter Richtung 45 Dollar.... erstmal!

https://www.investorsobserver.com/news/stock-update/will-axsome-therapeutics-inc-axsm-stay-at-the-top-of-the-healthcare-sector

https://m.aktiencheck.de/news/Artikel-Axsome_Therapeutics_Aktie_So_kann_es_nicht_weitergehen-14085869

rolling stones

FDA to perform Axsome facility inspection prior to AXS-07 action date https://seekingalpha.com/news/3796953-fda-to-perform-axsome-facility-inspection-prior-to-axs-07-action-date-shares-rise-3 Axsome Therapeutics (NASDAQ:AXSM) said that it was informed by the FDA that it should be able to perform a required inspection of a contract manufacturing facility prior to the PDUFA date of April 30, 2022 for AXS-07. ... The FDA had previously told the company that due to COVID-19-related travel restrictions it might not be able to conduct the inspection prior to the April action date. The AXS-07 NDA for migraine is backed by two late-stage trials.

https://www.marketscreener.com/quote/stock/AXSOME-THERAPEUTICS-INC-24949017/news/AXSOME-THERAPEUTICS-INC-Other-Events-form-8-K-37806581/ On February 1, 2022, Axsome and Baudax Bio, Inc. ("Baudax") entered into a Litigation Discontinuance Agreement pursuant to which Baudax was to voluntarily dismiss, with prejudice, its lawsuit against the Company in the United States District Court for the District of Delaware (the "Baudax Action").    ... As part of the resolution of the Baudax Action, Baudax executed a covenant not to sue pursuant to which Baudax will refrain from commencing any future litigation relating to AXS-07. Also in connection with the resolution, the Company made a one-time payment of $312,500 to Baudax, and the Company has not incurred any obligation to pay any royalty or other contingent consideration nor has it agreed to any other restriction on its manufacture or distribution of AXS-07.

Man erwartet zumindest etwas positives. Zumindest geht man davon aus, dass das was nun nachgereicht wurde nun auch zur Zulassung führt. Aber wissen tun wir es natürlich erst, wenn es einen entsprechenden Press releases gibt 👐

Kann aber muss nicht sein 😉 höre dies seit Monaten.. hab das Geld derzeit anderst investiert 🙂

Chris, du hattest deine Chance, Februar wird unser Monat